Vistagen Therapeutics (VTGN) News Today → Will this $2 AI stock double overnight? (From Behind the Markets) (Ad) Free VTGN Stock Alerts $4.72 -0.11 (-2.28%) (As of 04/24/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineVistagen Therapeutics: A Pipeline With Potential In Anxiety And Depressionseekingalpha.com - April 24 at 1:20 PM7 Stocks Under $15 Predicted to Boom in the Next 2 Yearsinvestorplace.com - April 19 at 7:13 AMMillionaire Makers: 3 Stocks Under $10 Set to Skyrocket by 2027investorplace.com - April 9 at 1:28 PMVistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conferencebusinesswire.com - April 9 at 8:30 AMVistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2finance.yahoo.com - April 1 at 9:00 AMSecret Superstars: 3 Unknown Stocks to Turn $5K into $100K by 2027investorplace.com - March 31 at 10:00 AMPDS Biotechnology GAAP EPS of -$1.39 beats by $0.06msn.com - March 28 at 8:13 PM30 Countries with the Lowest Depression Ratesfinance.yahoo.com - March 26 at 7:51 AMVistagen Therapeutics (NASDAQ:VTGN) Share Price Crosses Below 50-Day Moving Average of $4.83marketbeat.com - March 20 at 6:39 AMWhy VistaGen Therapeutics Is A Buy: Fasedienol Potential For Anxiety Treatmentsseekingalpha.com - March 17 at 8:48 AMVTGN Apr 2024 10.000 callfinance.yahoo.com - March 16 at 12:07 AMThis overlooked corner of women's health could be a $350 billion market opportunitycnbc.com - March 15 at 2:33 PMVistagen to Present at Stifel 2024 Virtual CNS Daysbusinesswire.com - March 11 at 8:30 AMVistagen to Present at TD Cowen 44th Annual Health Care Conferencefinance.yahoo.com - February 28 at 10:46 AMVistagen to Present at TD Cowen 44th Annual Health Care Conferencebusinesswire.com - February 28 at 8:30 AMVistagen Therapeutics Stock (NASDAQ:VTGN), Short Interest Reportbenzinga.com - February 22 at 10:14 AMDoes VistaGen Therapeutics, Inc. (VTGN) Have the Potential to Rally 160% as Wall Street Analysts Expect?finance.yahoo.com - February 21 at 1:53 PM3 Revolutionary Biotech Stocks Poised for 10X Surgeinvestorplace.com - February 19 at 12:24 PMFY2024 EPS Estimates for Vistagen Therapeutics, Inc. Boosted by Analyst (NASDAQ:VTGN)marketbeat.com - February 16 at 8:47 AMBuy Rating Affirmed for VistaGen: Promising Clinical Results and Strong Financial Outlookmarkets.businessinsider.com - February 15 at 6:43 PMVistagen Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lagfinance.yahoo.com - February 15 at 8:42 AMVistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q3 2024 Earnings Call Transcriptfinance.yahoo.com - February 15 at 8:42 AM3 Hidden-Gem Biotech Stocks Ready to Ride a Massive Market Waveinvestorplace.com - February 14 at 3:45 PMVistagen Therapeutics Inc VTGNmorningstar.com - February 13 at 8:11 PMRecap: Vistagen Therapeutics Q3 Earningsbenzinga.com - February 13 at 8:11 PMVistagen Therapeutics files for $350M mixed shelfmsn.com - February 13 at 8:11 PMVistagen Reports Fiscal 2024 Third Quarter Financial Results and Provides Corporate Updatefinance.yahoo.com - February 13 at 8:11 PMVistagen Therapeutics Inc (VTGN) Reports Fiscal 2024 Q3 Results: A Closer Look at Financials ...finance.yahoo.com - February 13 at 8:11 PMVistagen Reports Fiscal 2024 Third Quarter Financial Results and Provides Corporate Updatebusinesswire.com - February 13 at 4:20 PMVistaGen Therapeutics Q3 2024 Earnings Previewmsn.com - February 12 at 10:36 PMVistaGen Therapeutics's Earnings: A Previewbenzinga.com - February 12 at 5:30 PMVistagen to Report Fiscal Year 2024 Third Quarter Financial Results and Host Corporate Update Conference Call on February 13, 2024finance.yahoo.com - February 7 at 3:58 PMVistagen Therapeutics (VTGN) Set to Announce Quarterly Earnings on Tuesdaymarketbeat.com - February 7 at 8:50 AMVistagen Therapeutics (NASDAQ:VTGN) Share Price Crosses Above Fifty Day Moving Average of $4.86marketbeat.com - February 3 at 4:25 AMVistaGen Therapeutics Inc (VTGN)investing.com - January 30 at 6:10 PMVistagen Therapeutics, Inc. (NASDAQ:VTGN) Sees Large Drop in Short Interestmarketbeat.com - January 26 at 9:40 AMVistagen Therapeutics Inc.thestreet.com - January 23 at 5:46 PMHow Vistagen (VTGN) Stock Stands Out in a Strong Industryfinance.yahoo.com - December 29 at 1:05 PMVistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic Painfinance.yahoo.com - December 27 at 12:32 PMVistaGen Therapeutics (VTGN) Price Target Increased by 8.33% to 13.26msn.com - December 16 at 2:11 PMVistagen Therapeutics, Inc. (NASDAQ:VTGN) Short Interest Down 21.4% in Novembermarketbeat.com - December 15 at 2:38 AMAnalysts Conflicted on These Healthcare Names: Bioventus (BVS), Cerevel Therapeutics Holdings (CERE) and VistaGen Therapeutics (VTGN)markets.businessinsider.com - December 8 at 10:01 AMVistagen shares move up after Jeffries upgrademsn.com - December 7 at 5:45 PMPre-market Movers: MLGO, ZVSA, CXM, WVE, AAMC…markets.businessinsider.com - December 7 at 7:44 AMUndervalued VistaGen Therapeutics, Analyst Highlights Potential In Anxiety Treatmentbenzinga.com - December 4 at 2:47 PMRetail investors are Vistagen Therapeutics, Inc.'s (NASDAQ:VTGN) biggest owners and were rewarded after market cap rose by US$12m last weekfinance.yahoo.com - November 29 at 8:15 AMVistagen climbs as Stifel launches at Buy on anxiety prospectsmsn.com - November 14 at 6:25 PMAnxiety-Focused Stock Vistagen Therapeutics Is An Undervalued Late-Stage Neurology Player: Analystmarkets.businessinsider.com - November 14 at 6:25 PMVistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q2 2024 Earnings Call Transcriptfinance.yahoo.com - November 11 at 5:51 PMVistaGen Therapeutics GAAP EPS of -$0.66 beats by $0.02, revenue of $0.28Mmsn.com - November 9 at 6:23 PM Get Vistagen Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VTGN and its competitors with MarketBeat's FREE daily newsletter. Email Address Will this $2 AI stock double overnight? (Ad)It's a tiny AI company fighting for a big piece of a $20 Billion Pentagon contract. What's more, this groundbreaking firm is trading for less than $2 a share! Click here to learn more >>> VTGN Media Mentions By Week VTGN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VTGN News Sentiment▼1.000.44▲Average Medical News Sentiment VTGN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VTGN Articles This Week▼22▲VTGN Articles Average Week Get Vistagen Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VTGN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: CTMX News ELYM News KPTI News NVCT News RPTX News FGEN News OPTN News CTXR News COYA News SGMT News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VTGN) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsFed launches fourth dollar overhaulStansberry Research1970’s computer coder issues shocking A.I. warningTradeSmithExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vistagen Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
